Blinatumamab is a bispecific T cell engaging antibody (BiTE), anti-CD19/CD3, that has shown efficacy in adult and pediatric patients with relapsed or refractory ALL (72, 73). Here, CD19 is linked to acute lymphoblastic leukemia.